Scientific publications

Co-author · 7th of 20 authors

Authors: Hassan A, Hussein M, Magdy R, Uludüz D, Özge A, Taşdelen S, Amirguliyev S, Şaşmaz T, Abdulghani MO, Moustafa RR et al.

Frontiers in Neurology. 2026;17:1860601 · doi:10.3389/fneur.2026.1860601 · PMID 42465551

An assessment of the quality of headache care in Egypt: the current position, the gaps identified and strategic directions for improving the service. It forms part of an international series of studies on how a headache service should be organised at national level.

Co-author · 12th of 47 authors

Authors: Ceren Akgör M, Saghır K, Can Aİ, Sahbaz FG, Özcelik EU, Atalar AC, Ergin N, Orun MO, Madani AA, Ibrahim EAA, Togha M, Amirguliyev S et al.

Frontiers in Neurology. 2026;17:1859536 · doi:10.3389/fneur.2026.1859536 · PMID 42428755

A multinational study across 14 countries: it examined how often headache related to fasting and going without food arises in people susceptible to primary headache. The findings provide a basis for advising patients with headache on their eating pattern.

Co-author · 4th of 6 authors

Authors: Kokoti L, Al-Karagholi MA, Zhuang ZA, Amirguliyev S, Amin FM, Ashina M

Cephalalgia. 2024;44(5):03331024241248211 · doi:10.1177/03331024241248211 · PMID 38729773

A randomised clinical trial, that is, the most reliable type of study, in which participants are allocated to groups at random. It showed that activation of potassium channels outside the blood vessels does not trigger a migraine attack. This result clarifies the role of the vascular component in the mechanism that starts migraine and bears on the choice of targets for future medications.

Co-author · 3rd of 8 authors

Authors: Do TP, Deligianni C, Amirguliyev S, Snellman J, Lopez CL, Al-Karagholi MA, Guo S, Ashina M

Brain. 2023;146(12):5224–5234 · doi:10.1093/brain/awad261 · PMID 37540009

A study in humans published in one of the most authoritative journals in neurology. It showed that a migraine attack can be provoked through an intracellular signalling pathway even when the CGRP receptor is blocked by a modern preventive medication. This explains why CGRP medications are not enough for some patients and shows that the treatment target should be sought in the next link of the chain.

First author

Authors: Amirguliyev S, Zhang P, Al-Karagholi MA, Do TP

Cephalalgia. 2022;42(13):1436–1442 · doi:10.1177/03331024221118925 · PMID 35929061

A letter to the editor. Professional remarks on the methodology of a trial measuring the effect that the spread of scientific articles on social media has on the number of citations they receive. Dr Sarkhan Amirguliyev is the first author of this work.

Co-author · 6th of 9 authors

Authors: Pellesi L, De Icco R, Alawie HY, Andersen M, Liang D, Amirguliyev S, Al-Karagholi MA, Amin FM, Sessa M

Expert Opinion on Drug Safety. 2021;20(4):467–474 · doi:10.1080/14740338.2021.1866537 · PMID 33337920

A systematic review and meta-analysis, that is, all the available studies combined by a single method and recalculated. It assessed the adverse effects of erenumab, a medication used in the preventive treatment of migraine. Work of this kind gives the doctor a reference point for explaining a medication’s safety profile to a patient.